A-PBITMO

A-PBITMO
Identifiers
	IUPAC name (Adamantan-1-yl)(3-pentyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methanone;
CAS Number	none;
Chemical and physical data
Formula	C23H30N2OS
Molar mass	382.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES S=C1N(C(=O)C23CC4CC(C2)CC(C3)C4)c2ccccc2N1CCCCC;
	InChI InChI=1S/C23H30N2OS/c1-2-3-6-9-24-19-7-4-5-8-20(19)25(22(24)27)21(26)23-13-16-10-17(14-23)12-18(11-16)15-23/h4-5,7-8,16-18H,2-3,6,9-15H2,1H3; Key:VUROLZZLDVMOQX-UHFFFAOYSA-N;

A-PBITMO is a synthetic cannabinoid receptor agonist that has been sold as a designer drug, first reported in Germany in July 2023,^[1] and also subsequently identified in Russia.^[2] It has an unusual 1,3-dihydrobenzimidazole-2-thione core structure which has not previously been seen in cannabinoid designer drugs.

References

↑ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
↑ Yurchenko RA, Yurchenko LV, Galetskaya IA, Novitsky MV, Pavlovets YS (February 2024). Psychoactive products market observation. Trend analysis (Report) (in Russian). Aipsin. doi:10.13140/RG.2.2.10176.92163.

[1] "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.

[2] Yurchenko RA, Yurchenko LV, Galetskaya IA, Novitsky MV, Pavlovets YS (February 2024). Psychoactive products market observation. Trend analysis (Report) (in Russian). Aipsin. doi:10.13140/RG.2.2.10176.92163.

[1]

[2]

See also

References